

# João Paulo Maia-de-Oliveira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6050304/publications.pdf>

Version: 2024-02-01

19  
papers

621  
citations

840776

11  
h-index

794594

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

848  
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychosis in <scp>NUS1</scp> de novo mutation: New phenotypical presentation. <i>Clinical Genetics</i> , 2021, 99, 475-476.	2.0	7
2	Changes in Cortisol but Not in Brain-Derived Neurotrophic Factor Modulate the Association Between Sleep Disturbances and Major Depression. <i>Frontiers in Behavioral Neuroscience</i> , 2020, 14, 44.	2.0	19
3	An Overview of Animal Models Related to Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 5-17.	1.9	138
4	Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial. <i>Frontiers in Psychology</i> , 2019, 10, 1234.	2.1	114
5	Effects of sodium nitroprusside in the prevention of schizophrenia-like symptoms induced by ketamine " A translational double-blind study. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 149-153.	0.6	3
6	Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week. <i>Schizophrenia Research</i> , 2015, 162, 211-215.	2.0	26
7	Paliperidone Palmitate for Refractory and Clozapine-Resistant Schizophrenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, e14-e16.	1.8	6
8	Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia. <i>BMC Neuroscience</i> , 2015, 16, 9.	1.9	29
9	The Effects of Sodium Nitroprusside Treatment on Cognitive Deficits in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 83-85.	1.4	24
10	Cognition in at-risk mental states for psychosis. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 57, 199-208.	6.1	41
11	Sodium nitroprusside, a nitric oxide donor for novel treatment of schizophrenia, may also modulate dopaminergic systems. <i>Schizophrenia Research</i> , 2014, 159, 558-559.	2.0	8
12	Sodium Nitroprusside Treatment of Clozapine-Refractory Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 761-763.	1.4	13
13	Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium Nitroprusside. <i>JAMA Psychiatry</i> , 2013, 70, 668.	11.0	125
14	Novel Targets for Development of Drugs for Treating Schizophrenia: Focus on Glycine, D-Serine and Nitric Oxide. <i>Journal of Microbiology and Biotechnology</i> , 2013, 23, 129-137.	2.1	7
15	Why we should use long-acting injectable antipsychotics more frequently. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, 217-218.	1.7	8
16	Nitric Oxide Plasma/Serum Levels In Patients With Schizophrenia: A Systematic Review And Meta-Analysis. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, 149-162.	1.7	29
17	A False Case of Clozapine-Resistant Schizophrenia. <i>Case Reports in Medicine</i> , 2010, 2010, 1-3.	0.7	2
18	Functional neuroimaging of minocycline's effect in a patient with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 550-552.	4.8	21

#	ARTICLE	IF	CITATIONS
19	Minocycline and psychoneuroimmunology in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1133-1134.	4.8	1